Market Chatter: Eli Lilly Expands in China with $3 Billion Supply Chain Investment

MT Newswires Live03-12 18:37

U.S. pharmaceutical company Eli Lilly committed an investment of $3 billion in China over the next decade, the South China Morning Post reported Wednesday.

The move is expected to improve the company's local supply chain and manufacturing capabilities in the country, the report said.

The drugmaker will invest in a domestic production and supply system for its oral solid preparations, as well as a high-volume manufacturing line for its orforglipron type 2 diabetes treatment, the report said.

The pledge will bring Eli Lilly's total investment in China to about $6 billion, the report said, citing a statement on WeChat.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment